TABLE 1.
Performance of participating laboratories in the National Gonococcal Antimicrobial Susceptibility Comparison Program between 2003 and 2012
| Laboratory code | No. of panels completed | Test method used | Antibiotics testeda |
Agreement between MICs of participant and modal MICs (% [no.]) | Concordance between interpretations of participant and modal interpretations (% [no.]) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEN | SPEC | TET | CX | CIP | CE | AZI | ERY | |||||
| 1 | 25 | Agar dilution | x | x | X | X | 97.52 (354/363) | 98.13 (367/374) | ||||
| 2 | 20 (2003–2012) | Agar dilution | X | X | X | X | X | X | X | X | 90.73 (499/550) | 91.80 (593/646) |
| 3 | 25 | Agar dilution (9 panels)/Etest (19 panels) | X | X | X | X | X | X | X | X | 96.15 (749/779) | 95.03 (917/965) |
| 4 | 25 | Etest | X | x | X | X | X | X | X | 97.99 (536/547) | 94.86 (701/739) | |
| 5 | 25 | Etest | X | X | X | X | X | X | 96.78 (542/559) | 93.42 (696/745) | ||
| 6 | 25 | Agar dilution | X | X | X | X | X | X | x | X | 95.44 (272/285) | 96.26 (720/748) |
| 7 | 25 | Etest | X | X | X | X | X | X | X | X | 94.29 (694/736) | 89.19 (751/842) |
| 8 | 18 (2004–2012) | Etest | X | x | X | X | X | X | 98.77 (400/405) | 95.87 (511/533) | ||
| 9 | 14 (2005–2011) | Agar dilution (9 panels)/Etest (5 panels) | X | X | X | X | X | 85.62 (250/292) | 85.71 (294/343) | |||
| 10b | 25 | Agar dilution (25 panels)/Etest (14 panels) | X | X | X | X | X | X | X | X | 96.00 (1,272/1,325) | 95.63 (1,138/1,190) |
a
A lowercase “x” indicates that the antibiotic was not tested for all panels. PEN, penicillin; SPEC, spectinomycin; TET, tetracycline; CX, ceftriaxone; CIP, ciprofloxacin; CE, cefixime; AZI, azithromycin; ERY, erythromycin.
b
Laboratory 10 is the NML, which started using the Etest in addition to agar dilution in 2006.